Revisiting Interleukin-12 as a Cancer Immunotherapy Agent

Pedro Berraondo; Iñaki Etxeberria; Mariano Ponz-Sarvise; Ignacio Melero

doi:10.1158/1078-0432.CCR-18-0381

Revisiting Interleukin-12 as a Cancer Immunotherapy Agent

Clin Cancer Res. 2018 Jun 15;24(12):2716-2718. doi: 10.1158/1078-0432.CCR-18-0381. Epub 2018 Mar 16.

Authors

Pedro Berraondo^{1

2

3}, Iñaki Etxeberria^{1

2}, Mariano Ponz-Sarvise^{2

4}, Ignacio Melero^{5

2

3

4}

Affiliations

¹ Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
² Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
³ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain.
⁴ Departments of Oncology and Immunology, University Clinic of Navarra (CUN), Pamplona, Spain.
⁵ Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. imelero@unav.es.

PMID: 29549160
DOI: 10.1158/1078-0432.CCR-18-0381

Abstract

IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNγ. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer. Clin Cancer Res; 24(12); 2716-8. ©2018 AACRSee related article by Hu et al., p. 2920.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Immunotherapy
Immunotherapy, Adoptive
Interleukin-12*
Neoplasms*
T-Lymphocytes, Regulatory

Substances

Interleukin-12